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Ibalizumab is a humanized, anti-CD4monoclonal anti-
body. It potently blocks HIV-1 infection and targets an
epitope in the second domain of CD4 without inter-
fering with immune functions mediated by interaction
of CD4 with major histocompatibility complex (MHC)
class IImolecules.We report here the crystal structure
of ibalizumab Fab fragment in complex with the first
two domains (D1-D2) of CD4 at 2.2 A˚ resolution. Ibali-
zumab grips CD4 primarily by the BC-loop (residues
121–125) of D2, sitting on the opposite side of gp120
and MHC-II binding sites. No major conformational
change in CD4 accompanies binding to ibalizumab.
Both monovalent and bivalent forms of ibalizumab
effectively block viral infection, suggesting that it
does not need to crosslink CD4 to exert antiviral
activity. While gp120-induced structural rearrange-
ments in CD4 are probably minimal, CD4 structural
rigidity is dispensable for ibalizumab inhibition. These
results could guide CD4-based immunogen design
and lead to a better understanding of HIV-1 entry.
INTRODUCTION
CD4, a cell-surface glycoprotein containing four immunoglobulin
domains (D1 to D4), has an essential role in both T cell activation
and HIV-1 (human immunodeficiency virus type-1) infection. As
a T cell coreceptor, CD4 interacts directly with major histocom-
patibility complex (MHC) class II molecules on the surface of
antigen presenting cells and helps recruit a tyrosine kinase,
p56lck, to facilitate activation of helper T cells, thereby modu-
lating adaptive immune responses (Doyle and Strominger,
1987; Xu and Littman, 1993). The interaction of CD4 with MHC
II has been defined by structural studies of a complex containing
2D CD4 and the murine I-Ak class II MHC molecule with a bound
peptide (Wang et al., 2001). The first domain (D1) of CD4 makes
direct contacts with the a2 and b2 domains of MHC II, suggest-
ing that T cell receptor and CD4 communicate with each other
through the peptide-MHC complex (Wang et al., 2001). HIV-11632 Structure 18, 1632–1641, December 8, 2010 ª2010 Elsevier Ltdexploits CD4 as its primary receptor for initial attachment and
for inducing formation of the coreceptor binding site on the
HIV-1 envelope glycoprotein gp120 (Dalgleish et al., 1984; Wyatt
and Sodroski, 1998). Encounter of the coreceptor by gp120 is
believed to be the crucial trigger for dissociation of gp120 and
a cascade of refolding events in the viral fusion protein gp41,
leading to fusion of viral and host cell membranes (Harrison,
2008). Comparison of crystal structures of gp120 core in the
CD4-bound and the unliganded conformations reveals molec-
ular details of the interaction of CD4 with gp120 and the accom-
panying structural rearrangements in the viral protein (Chen
et al., 2005; Kwong et al., 1998). The gp120 core contains two
closely associated domains, named ‘‘inner’’ and ‘‘outer.’’ In the
CD4-bound conformation, the relative orientations of the two
domains are fixed by a four-strand b sheet, the ‘‘bridging sheet,’’
formed by two b hairpins, the stem of the V1-V2 variable loop
from the inner domain and a hairpin that projects from the outer
domain. D1 of CD4 interacts, primarily through the C00 edge, with
both the inner and outer domains, as well as with the bridging
sheet (Kwong et al., 1998). CD4 binding results in large rear-
rangements of the inner domain, leading to formation of the
bridging sheet (Chen et al., 2005). Together with the V3 variable
loop, the bridging sheet makes up the binding site for coreceptor
(Huang et al., 2007; Rizzuto et al., 1998). The ectodomain of CD4
could project up to 115 A˚ from the cell surface, with D1 at the
membrane-distal end (Wu et al., 1997). Conformational changes
in gp120, CD4 or both would be needed to bring the bound
gp120 (or the virus) close to the coreceptor, a seven-transmem-
brane receptor embedded in cell membrane.
Ibalizumab (also known as Hu5A8 or TNX-355), is a humanized
IgG4 monoclonal antibody (mAb) derived from a mouse anti-
body, 5A8, which binds D2 of CD4 and blocks HIV-1 infection
in vitro (Burkly et al., 1992; Dimitrov, 2007; Reimann et al.,
1997). Ibalizumab has also been shown to neutralize a broad
spectrum of HIV-1 primary isolates in vitro, and to effectively
reduce plasma viral loads and increase CD4+ T cell counts in
both SIV (simian immunodeficiency virus)-infected rhesus
monkeys and HIV-1 infected patients (Jacobson et al., 2009;
Kuritzkes et al., 2004; Reimann et al., 2002). Because of its
potency and breadth, ibalizumab is currently being evaluated
as a potential therapeutic antibody in a phase IIb clinical trial
conducted by TaiMed Biologics, Inc. (Jacobson et al., 2009).
Previous mutagenesis studies suggest that the epitope ofAll rights reserved
Table 1. Neutralization of 12 Selected HIV-1 Isolates by Ibalizumab IgG and Fab, Soluble CD4 and 4E10
Virus Clade
Ibalizumab IgG Ibalizumab FAb sCD4 4E10
IC50 Titer
a MPI (%)b IC50 Titer MPI (%) IC50 Titer MPI (%) IC50 Titer MPI (%)
SF162.LS B >100 33 >100 24 0.13 100 11.10 73
MN B 0.24 71 >100 39 <0.02 100 0.14 100
HxB2.DG B 2.20 52 >100 26 <0.02 100 0.19 100
SC422661.8 B 0.03 81 0.90 59 8.80 75 1.20 95
PVO.4 B 0.02 92 0.18 67 8.50 90 50.00 50
QH0692.42 B 0.14 78 3.40 59 2.10 100 7.40 78
ZM53M.PB12 C 0.13 78 >100 47 6.80 98 10.10 89
Du156.12 C 0.01 100 0.02 99 22.30 71 0.30 100
Du422.1 C 0.02 97 0.09 91 9.30 85 10.20 88
Q769.d22 A >100 48 >100 27 1.10 100 3.70 88
Q461.e2 A 0.10 78 53.80 57 17.80 90 28.50 65
Q259.d2.17 A 0.02 90 0.32 74 8.80 97 11.10 74
See also Figure S1 and Table S2.
a 50% inhibitory concentration (mg/ml).
bMaximum percentage of inhibition.
Structure
CD4-Ibalizumab Complexibalizumab on CD4 does not overlap with the binding site of
gp120 or MHC class II molecules, consistent with the observa-
tions that the antibody does not interfere with viral attachment
and that it is well tolerated when infused into patients (Burkly
et al., 1992; Moore et al., 1992; Song et al., 2010). Residues
121–124 and 127–134 in D2 of CD4 were found to be critical
for 5A8 binding, and it was reported that only the bivalent form
of the antibody was effective in blocking HIV-1 infection (Burkly
et al., 1992). These results implied that the antibody might exert
its antiviral activity by crosslinking CD4, thereby preventing
certain postattachment events required for HIV-1 entry.
To define the ibalizumab epitope at the atomic level and to
reveal potential structural changes in CD4 induced by binding
to the antibody, we have determined the crystal structure of
the Fab fragment of ibalizumab in complex with the two
N-terminal domains of human CD4 at 2.2 A˚ resolution. The anti-
body primarily contacts the BC-loop in D2 of CD4, at the D1-D2
junction on the opposite side of both gp120 and MHC class II
binding sites. Small, local conformational changes in CD4 occur
at the binding interface, but they do not propagate to other
regions to have a significant impact on the receptor function.
Both the IgG and Fab forms of ibalizumab effectively block viral
entry by certain HIV-1 isolates, ruling out the possibility that
crosslinking of CD4 is required for its antiviral activity. We have
also shown that interaction with gp120 does not lead to major
structural rearrangements in the ectodomain of CD4, and that
structural rigidity in the membrane-bound CD4 does not play
a role in ibalizumab inhibition. These results could guide
CD4-based immunogen design for eliciting ibalizumab-like anti-
body responses against HIV-1 infection, and lay a foundation for
further investigations to better understand HIV-1 entry.
RESULTS
Inhibition of HIV-1 Infection by Ibalizumab IgG and Fab
It was previously reported that only bivalent forms of mouse
mAb 5A8 were effective in blocking HIV-1 entry (Burkly et al.,Structure 18, 1632–161992). To verify this observation using ibalizumab, we chose
a panel of HIV-1 Env pseudoviruses, including three labora-
tory-adapted isolates and nine primary isolates from clades
A, B, and C, to test inhibition by its bivalent IgG and monova-
lent Fab fragment. The antigenic diversity of HIV-1 is also well
represented by the selected viruses, as their sensitivities to
neutralization by soluble CD4 or a broadly neutralizing, anti-
gp41 antibody 4E10 differ significantly (Table 1). Contrary to
previous findings, both IgG and Fab of ibalizumab can block
infection by most viruses; however, inhibition strengths of biva-
lent IgG and monovalent Fab vary greatly among different
isolates (Figure 1 and Table 1; see Figure S1 available online).
In general, the three laboratory-adapted strains, SF162.LS,
MN-3, and HxB2.DG, are less sensitive to ibalizumab than
the primary isolates. Two of the patient isolates, Du156.12
and Du422.1, both from clade C, are the most sensitive ones
among all the viruses tested, with almost equal sensitivity to
the IgG and to the Fab. For all other primary strains, the IgG
is indeed more potent than the Fab, but the latter does reduce
viral infection of all isolates tested. In addition, Fab and bivalent
F(ab’)2 also show comparable inhibitory activity against several
HIV-1 isolates (Table S2). Thus, we conclude that the bivalency
of ibalizumab is not required for its antiviral activity, but its size
may have an impact. The discrepancy between this work and
the published results is likely caused by the limited number
of laboratory-adapted strains and the cell-cell fusion assay
used for the previous study (Burkly et al., 1992). Ibalizumab
exhibits a relatively unusual, strain-dependent inhibition
pattern, where the neutralization curve plateaus below 100%
inhibition with increase of the antibody concentration (Figure 1;
Figure S1) (designated as maximum percent inhibition (MPI) in
Table 1). The reason for this phenomenon is unknown, as the
viruses used were all pseudotyped with homogenous Env
molecular clones and CD4-independent HIV-1 isolates are
extremely rare (Kolchinsky et al., 2001). Regardless, viruses
with MPI less than 100% could potentially escape from ibalizu-
mab inhibition.41, December 8, 2010 ª2010 Elsevier Ltd All rights reserved 1633
Figure 1. Inhibition of Representative HIV-1 Isolates by Ibalizumab
IgG and Fab
HIV-1 primary isolates, Du156.12 (clade C), QH0692.42 (clade B),
ZM53M.PB12 (clade C), and Q769.d22 (clade A) were analyzed for inhibition
by the anti-CD4 monoclonal antibody ibalizumab using a luciferase-based
virus neutralization assay with TZM.bl cells. Serial dilutions of ibalizumab in
the bivalent IgG form (filled square) or the monovalent Fab form (open square)
were tested for neutralization against each virus. Fifty percent of inhibition is
indicated by a dashed, horizontal line. IC50 values and MPI (maximum percent
inhibition) are summarized in Table 1. The experiments were repeated twice
with similar results. See also Figure S1 and Table S2.
Structure
CD4-Ibalizumab Complex
1634 Structure 18, 1632–1641, December 8, 2010 ª2010 Elsevier LtdStructure of the Complex of ibalizumab Fab and Soluble
2 Domain CD4
To define the epitope of ibalizumab precisely and to gain molec-
ular insights on whether ibalizumab binding could block CD4
receptor function, we have determined the crystal structure of
the complex of its Fab and human CD4 at 2.2 A˚ resolution. The
Fab fragment of ibalizumab was produced by papain digestion
and purified by protein A affinity and gel-filtration chromatog-
raphy. A two-domain fragment of human CD4 (residues 1–182)
with a C-terminal His-tag, produced in insect cells, was mixed
with ibalizumab Fab, and the complex was further purified by
gel-filtration chromatography. The complex was crystallized by
hanging-drop vapor diffusion with a mother liquor containing
3MNamalonate (pH 5.5). The crystals diffract to 2.2 A˚ resolution
and belong to space group P212121 (a = 52.2, b = 66.3,
c = 266.6 A˚), with one Fab-CD4 complex per crystallographic
asymmetric unit. The structure was determined by molecular
replacement using 2D CD4 and a library of Fab coordinates as
searchmodels byMOLREP and Phaser (Aoki et al., 2009;McCoy
et al., 2007; Vagin and Teplyakov, 1997). Complementarity
determining regions (CDRs) of both heavy and light chains of iba-
lizumab were rebuilt iteratively in O (Jones and Kjeldgaard,
1997), and the final model was refined with an Rwork of 19.3%
and an Rfree of 22.4% (Table S1).
As shown in Figure 2, ibalizumab grips CD4 mainly by direct
contacts between both its heavy and light chains, and the BC-
loop (residues 121–125) in D2 of CD4. These interactions are
consistent with the previous mutagenesis results (Burkly et al.,
1992; Song et al., 2010), but another segment (residues
127–134) in CD4, previously suggested to be critical for mAb
5A8 binding (Burkly et al., 1992), barely makes contact with the
antibody. There is a distorted disulfide (S-S) bond between resi-
dues Cys130 and Cys159, which are located in two antiparallel
beta strands, respectively, and the geometry required for the
S-S bond is not favorable (Wang et al., 1990). Therefore, any
deletions in the neighboring residues could further disfavor the
formation of this S-S bond and in turn affect the conformation
of the core epitope, the BC loop. Amore recent epitope-mapping
study on ibalizumab by point mutation has indicated that the
segment (residues 127–134) is less critical (Song et al., 2010).
As shown in Figure 3A, the tip of the BC-loop in CD4 is sand-
wiched between the CDR H3 and CDR L3 of ibalizumab.
Pro122 of CD4 is tightly packed against Tyr30A, Tyr32, and
Tyr92 of the L-chain. Additional contacts include an extensive
hydrogen bond network formed among residues 120–126 of
CD4 and ibalizumab, either directly or mediated by water mole-
cules. Clearly, the BC-loop constitutes the core epitope of ibali-
zumab (Figure 3A). The second major contact involves residues
164–165 (the short FG loop in D2) of CD4 and the ibalizumab
H-chain (Figure 3B). The FG loop is surrounded by all three
CDRs from the heavy chain. Binding to ibalizumab induces
a flip of the peptide bond between Asn164 and Gln165, resulting
in a flip of the FG loop (Figure 3B). The induced conformation is
stabilized by a number of hydrogen bonds, indicating that the FG
loop forms an important part of the epitope. This conformational
change in CD4 triggered by ibalizumab binding is nevertheless
entirely local and does not propagate to other regions. Thus, it
appears to have no significant impact on CD4 function. The third
major contact is made by interaction of the tip of CDR L1with theAll rights reserved
Figure 2. Structure of the Complex of 2 domain CD4 and the Fab
Fragment of Ibalizumab
(A) Top and side views of the overall structure of 2D CD4 in complex with iba-
lizumab Fab, shown in ribbon representation. CD4 is in green (lighter green for
D2 and darker green for D1), the heavy chain of ibalizumab in red, and the light
chain in magenta. The BC-loop in the second domain of CD4, which consti-
tutes the core epitope, and the CDR loops of ibalizumab are all indicated.
(B) Surface representation of the complex. CD4 and ibalizumab are shown in
the same color scheme as in (A).
See also Figures S2 and S4 and Table S1.
Figure 3. Closeup of Major Contacts between CD4 and Ibalizumab
(A) Residuesmaking direct contacts between the heavy and light chains of iba-
lizumab and the BC-loop (residues 121–125) of D2 in CD4. The heavy and light
chains of ibalizumab are shown by surface representation in red and magenta,
respectively, and the residues that make contacts with CD4 are also shown by
stickmodel in the same color scheme. The BC-loop of CD4 is in green in ribbon
diagram and the residues interacting with ibalizumab are shown by stickmodel
with carbon atoms in yellow, nitrogen in blue and oxygen in red.
(B) Contacting residues between the FG loop (residues 164, 165) of D2 in CD4
and the ibalizumab heavy chain. The residues that make direct contacts with
the FG loop of CD4 in the heavy chain are shown by stick model in red. The
FG loop of CD4 is shown in ribbon diagram in green with residues 164 and
165 in stick model in the same color scheme as in (A). The conformation of
the two residues in the unbound CD4 is also shown in cyan; a flip of the loop
upon binding to ibalizumab is evident.
See also Figure S3 and Table S1.
Structure
CD4-Ibalizumab ComplexEF loop in D1 of CD4. The side chains of Tyr30A and Thr30C of
L-chain form hydrogen bonds with the main chain carbonyl of
Ser79 and Glu77, respectively. Thus, D1 also contributes
substantially to the ibalizumab epitope. Overall, there are no
major conformational changes within CD4 upon binding to ibali-
zumab that could propagate to other regions.
The binding site of ibalizumab does not overlap with the
binding site for MHC II (Figures S2 and S3), in agreement with
the observation that ibalizumab is nonimmunosuppressive
(Boon et al., 2002). Since the gp120 binding site on CD4 doesStructure 18, 1632–16not overlay that of ibalizumab either (Figures S2 and S3), consis-
tent with the previous findings that binding of mAb 5A8 to CD4
does not reduce CD4 affinity to gp120, nor does it block CD4
binding to HIV-1 virions (Moore et al., 1992), and with our result
that ibalizumab does not hinder interaction between CD4 and
a stable, homogenous HIV-1 gp140 trimer (Figure S4), how
does ibalizumab block HIV-1 infection? Earlier studies sug-
gested that ibalizumab may exert its antiviral activity by cross-
linking CD4, thereby impeding the postbinding movement of
CD4. Our finding that the monovalent form of ibalizumab inhibits
at least some HIV-1 isolates has ruled out the possibility that
crosslinking of CD4 plays a major role in neutralization by41, December 8, 2010 ª2010 Elsevier Ltd All rights reserved 1635
Table 2. SAXS Analysis of 2D CD4-gp120 Core and 4D CD4-gp120 Core Complexes
Protein Mass (kDa)
Rg (A˚) Guinier
analysis
Rg (A˚) P(r)
analysis
Dmax (A˚) P(r)
analysis
Dmax (A˚) crystal
structure
2D CD4 21.0 22.10 ± 0.41 22.42 ± 0.10 70 67
4D CD4 41.2 34.80 ± 0.14 35.35 ± 0.14 118 115
gp120 core 66.0 30.90 ± 0.13 30.31 ± 0.06 90 83
2D CD4-gp120 core 87.0 36.00 ± 0.27 36.71 ± 0.08 110 102
4D CD4-gp120 core 107.2 46.80 ± 0.26 47.54 ± 0.17 155 152
See also Figures S5–S7.
Structure
CD4-Ibalizumab Complexibalizumab. Another possibility is that the entire ectodomain of
CD4 may undergo, upon binding to gp120, certain structural re-
arrangements that are required for the viral entry and could be
blocked by ibalizumab.
Binding by gp120 Does Not Lead to Large
Conformational Changes in Soluble, 4-Domain CD4
Gp120-CD4 interaction triggers large structural rearrangements
in gp120 to form the coreceptor binding site. In contrast, gp120
binding does not alter the structure of the first two domains of
CD4 (Kwong et al., 1998). Based on reconstructions of 2 domain
CD4-gp120 and 4 domain CD4-gp120 complexes derived from
small angle X-ray scattering (SAXS) data, Ashish et al. (2008)
have proposed that interaction with gp120 induces a large
conformational change in the ectodomain of CD4, in which
the first two domains (D1-D2) fold back along the D2-D3 hinge
region onto the third and fourth domains (D3-D4) (Ashish et al.,
2008). The two complexes appeared to have a similar Dmax (the
largest dimension of the protein or protein complex) or Rg
(radius of gyration) in this study. Close examination of the
D2-D3 linker region in the crystal structure of 4D CD4 leads
us to believe that such a dramatic, jackknife-type rearrange-
ment is highly unlikely, because it would lead to serious side-
chain clashes between residues in D2 and D3, if CD4 had to
bend by 180 degrees (Wu et al., 1997). Furthermore, in the
Ashish et al. study, the use of a full-length gp120 protein and un-
purified gp120-CD4 complexes is questionable and could
complicate interpretation of the SAXS data (Ashish et al.,
2008). We decided to reexamine this issue by using the SAXS
technique to analyze the complexes of soluble CD4 with
gp120 core, for which the structure is much better understood
than that of the full-length gp120. To ensure the conformational
homogeneity of the samples before SAXS data collection, all the
proteins and protein complexes were purified by gel-filtration
chromatography on a S200 column (Figure S5). The Rg of
each sample was derived from both Guinier analysis and
distance distribution function P(r) analysis (Figure S6). As
summarized in Table 2, Rgs obtained from the two different
analyses are in excellent agreement for each sample. In partic-
ular, Rg for the 2 domain CD4-gp120 core complex is 36.0 A˚
while Rg for the 4 domain CD4-gp120 core complex is 47.0 A˚.
The derived Dmax values for these two complexes are quite
different and consistent with those measured directly from the
crystal structure or the modeled 4D CD4-gp120 structure
assuming no conformational changes in 4D CD4 when bound
to gp120 (Table 2; Figure S7). We conclude that there are no
dramatic, gp120-induced conformational changes in the ecto-1636 Structure 18, 1632–1641, December 8, 2010 ª2010 Elsevier Ltddomain of CD4. It remains possible that CD4 could bend by
a few degrees at the D2-D3 junction, which may not be detect-
able by SAXS.
Impact of the Structural Rigidity in the Ectodomain
of CD4 on Ibalizumab Inhibition
Since CD4 does not undergo a jackknife-type change when
bound to gp120, its ectodomain may need to swing toward the
membrane as a rigid body in order to bring its D1 at the
membrane-distal end and the bound gp120 close to the core-
ceptor. If this large swing of CD4 is required for gp120 to access
coreceptor, ibalizumab could potentially block or retard this crit-
ical movement by binding to D2. To test this hypothesis, we
introduced flexibility into the ectodomain of CD4 by replacing
D3-D4 of CD4 with flexible, artificial linkers of various lengths.
Ibalizumab would not be able to block HIV-1 infection mediated
by theseCD4 variants if the structural rigidity of CD4were neces-
sary for inhibition. We created four CD4 variants with the first two
domains (D1-D2) connected directly to the transmembrane (TM)
segment and cytoplasmic tail by a flexible linker (CD4-L1,
CD4-L2, CD4-L3, and CD4-L4 in Figure 4). Two additional vari-
ants were also constructed, with either a 5 residue deletion (resi-
dues 367–371; TPVQP) in the linker region betweenD4 and TMof
CD4 (CD4-D5) to rigidify the ectodomain or the entire C-terminal
half of CD4 replaced by the human CD8a hinge region and TM
(CD4-CD8TM). The latter two constructs were previously re-
ported to be able to support HIV-1 infection, albeit at reduced
efficiency (Moir et al., 1996; Poulin et al., 1991). When introduced
into a 293T cell line stably expressing human CCR5 (ACTOne
CCR5 cells) by transient transfection, all CD4 variants except
for CD4-D5 express at a similar level on the cell surface as
does the wild-type CD4 construct, as judged by flow cytometry
(Figure 4; Figure S8). They can also support HIV-1 entry when in-
fected with a recombinant HIV-1 SC422661.8 Env pseudotyped
virus expressing a luciferase reporter gene (Figure 4; Figure S9A),
but the efficiency varies and roughly correlates with the length of
the flexible linker. All CD4 variants remain sensitive to inhibition
by ibalizumab, however, with IC50 and MPI values similar to
those of wild-type CD4 (Figure 4; Figure S9B), suggesting that
structural rigidity within the CD4 ectodomain is not essential
for either HIV-1 entry or for inhibition by ibalizumab. These
results further confirm that D3-D4 of CD4 is dispensable for its
receptor function, arguing against the jackknife model proposed
previously (Ashish et al., 2008).
Modeling of the structure of the complex of ibalizumab,
4-domain CD4 and gp120 core containing the V3 loop suggests
that ibalizumab is distant from the coreceptor binding site, whichAll rights reserved
Figure 4. Impact of Flexibility in the CD4 Ectodomain on HIV-1 Inhibition by Ibalizumab
To introduce flexibility in the ectodomain of CD4, four variants with its D3-D4 (residues 179–365) substituted by a flexible linker, GGGGS (CD4-L1),
GGGGSGGGGSGGGGS (CD4-L2), GGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGS (CD4-L3) and GGGGSGGGGSGGGGSGGGGSGGGGSGGGGS
GGGGSGGGGSGGGGS (CD4-L4) were generated. Two additional CD4 variants were also constructed with either a 5 residue (residues 367–371; TPVQP) dele-
tion (CD4-D5) or the entire D3-D4 and TM (residues 179–433) replaced by a human CD8a hinge region and TM (residues 115–214) (CD4-CD8TM). ACTOne CCR5
cells were transfected with wild-type CD4 and six variants. Surface expression levels of CD4 and CCR5 were detected by fluorescence-activated cell sorting
(FACS) analyses and the mean fluorescence intensity (MFI) values are summarized. The relative infectivity of these target cells by a recombinant HIV-1 Env pseu-
dovirus, SC422661.8, expressing the firefly luciferase reporter gene is shown by relative luminescence units (RLU). Inhibition of this HIV-1 Env pseudovirus by
ibalizumab IgG are reported as IC50 values andMPI (maximum percent inhibition). The experiments were repeated twice with similar results and one set of data is
shown. See also Figures S8 and S9.
Structure
CD4-Ibalizumab Complexincludes the bridging sheet and V3 loop (Figure S3B). It is there-
fore unlikely that ibalizumab would directly block gp120 binding
to the coreceptor on the cell surface.
DISCUSSION
Ibalizumab is a humanized, anti-CD4monoclonal antibody and is
currently being evaluated as a potential anti-HIV-1 therapeutic
agent. We have determined the atomic structure of the Fab frag-
ment of ibalizumab in complex with the first two N-terminal
domains (D1-D2; residues 1–182) of human CD4 at 2.2 A˚ resolu-
tion. The BC-loop of D2 in CD4 near the D1-D2 junction consti-
tutes the core epitope of ibalizumab, which does not overlap
with the binding site of either gp120 or MHC class II. The crystal
structure provides a clear explanation, at atomic resolution, of
why ibalizumab does not directly block HIV-1 attachment or
interfere with immune functions mediated by CD4, in agreement
with previous mutagenesis studies (Burkly et al., 1992; Song
et al., 2010). Ibalizumab binding induces only a small, local
movement of the FG loop in CD4, but this change does not prop-
agate to other regions and does not lead to any significant
consequences for receptor function. We have also shown that
both IgG and Fab forms of ibalizumab effectively block viral entry
by certain HIV-1 isolates, ruling out the possibility that the anti-
body exerts its antiviral activity by crosslinking CD4. We have
further shown that the ectodomain of CD4 does not undergoStructure 18, 1632–16any dramatic, gp120-induced structural rearrangements, but
that its structural rigidity is not required for ibalizumab to inhibit
HIV-1 infection. Finally, structure modeling indicates that ibalizu-
mab binding to CD4 should not prevent the envelope from
binding to CCR5 on the target-cell surface, suggesting that iba-
lizumab acts on subsequent steps after gp120 engagement with
coreceptor. Our findings could guide strategies for optimizing
CD4-based immunogens to induce ibalizumab-like antibodies
and thus facilitate development of novel therapeutic agents
against HIV-1 infection. Ibalizumab could also be used as
a unique reagent to probe CD4 receptor function for a better
understanding of HIV-1 entry.
Structure-Based CD4 Immunogen Design to Develop
Therapeutic Antibodies
Conventional HIV vaccine strategies focusing on inducing virus-
specific humoral and cellular immune responses have failed to
protect against HIV-1 infection in clinical trials to date (Pitisutti-
thum et al., 2006; Rerks-Ngarm et al., 2009), primarily due to the
enormous challenge of HIV-1 evolution and global diversity.
There has been increasing recognition that conserved host
factors could be targeted for antiviral purposes. For instance,
viruses using CCR5 (R5 viruses) are responsible for viral trans-
mission, and individuals who express the CCR5D32 mutation
are healthy but almost completely resistant to HIV-1 infection
(Dean et al., 1996; Liu et al., 1996). Thus, CCR5 has been41, December 8, 2010 ª2010 Elsevier Ltd All rights reserved 1637
Structure
CD4-Ibalizumab Complexexplored as an antiviral target to block HIV-1 transmission for
both therapeutic and vaccine development. CCR5 antagonists,
such as maraviroc, have proven safe and effective in HIV-1-in-
fected patients, and a humanized anti-CCR5 monoclonal anti-
body PRO140 is currently in clinical trials (Gulick et al., 2008;
Jacobson et al., 2008). Targeting the primary receptor, CD4,
might raise serious safety concerns, however, because of its
important role in regulating adaptive immune responses. The
ongoing clinical trial of ibalizumab has demonstrated the poten-
tial utility of a nonimmunosuppressive, anti-CD4 antibody in
anti-HIV-1 strategies (Jacobson et al., 2009). How can the
atomic structure of the complex of ibalizumab and CD4 help
this endeavor? With precise knowledge of the ibalizumab
epitope, an immediate application would be to modify human
CD4 to expose only this unique epitope for inducing ibalizu-
mab-like monoclonal antibodies in animals. The more the candi-
dates like ibalizumab we have for humanization, perhaps with
even better potency or pharmacokinetic properties, the more
likely will this strategy eventually succeed. Approaches to
selectively expose the ibalizumab epitope on CD4 could involve
strategically placing N-linked glycans to cover the surface of
2 domain CD4 except at the D1-D2 junction or grafting the
epitope onto other Ig domain scaffolds. The high-resolution
crystal structure presented here would be indispensible for
this type of protein-engineering problem. If such modified
immunogens prove effective in eliciting ibalizumab-like anti-
bodies in animals, a possible next step could be to test them
directly in humans in conjunction with approaches to break
tolerance as a vaccine strategy. However, it could still remain
risky since ibalizumab contains IgG4 heavy chain by design to
minimize Fc-mediated CD4+ T cell depletion (Reimann et al.,
1997), while IgG1 and IgG2 may predominate antibody
responses following vaccination and these two subclasses
could bind Fc receptors and lead to CD4+ T cell depletion
(Clynes et al., 2000; Raghavan and Bjorkman, 1996).
Molecular Mechanism of HIV-1 Inhibition by Ibalizumab
Our current work has yet to lead to a definitive picture of how
ibalizumab blocks HIV-1 infection, but it has ruled out several
possibilities. First, previous studies have suggested that ibalizu-
mab might exert its antiviral activity by crosslinking CD4 (Burkly
et al., 1992), thereby impeding the postbinding movement of
CD4 or disrupting certain specific configurations for multiple
CD4 molecules, e.g., if three CD4 molecules are required to
trigger a gp120 trimer to promote fusion. Our results show
that the monovalent form of ibalizumab effectively inhibits
most of the HIV-1 isolates tested, ruling out the possibility that
crosslinking of CD4 plays a major role in ibalizumab inhibition.
Ibalizumab does reduce the surface level of CD4 on the target
cells, but the downregulation is only transient and clearly not
sufficient to account for the potent antiviral activity of the anti-
body (Y. Huang and D.D.H., unpublished data). We further
show that soluble, 4D CD4 maintains an extended conformation
even in complex with gp120 core, consistent with our structure-
based prediction that a jackknife rearrangement of D1-D2
relative to D3-D4, proposed previously (Ashish et al., 2008), is
energetically unfavorable and highly unlikely. Thus, we conclude
gp120 binding does not lead to any dramatic conformational
change in the ectodomain of CD4. It is possible that the1638 Structure 18, 1632–1641, December 8, 2010 ª2010 Elsevier LtdD2-D3 junction remains flexible and D1-D2 could bend relative
to D3-D4 by a modest extent in the presence of gp120. Ibalizu-
mab would probably not interfere with such a modest move-
ment, even if such a change were required for viral entry.
Moreover, ibalizumab does not induce any obvious structural
changes in CD4 that could impede receptor function. The length
of 4D CD4 is at least 115 A˚, the D1-D2 and D3-D4 junctions are
very rigid, and the D2-D3 junction has only limited flexibility
(Wang et al., 1990; Wu et al., 1997). A large swing of CD4 to
bring D1 at the membrane-distal end toward membrane along
the hinge region between D4 and TM might be required to bring
the bound gp120 to the vicinity of co-receptor. Attachment of
ibalizumab to D1-D2 could affect the kinetics of the swing and
thus block docking of gp120 onto coreceptor. If this were the
case, we predicted that replacing D3-D4 with a flexible linker
would allow D1-D2 to bend over freely and would thus confer
resistance to ibalizumab. Our results in Figure 4 clearly argue
against this possibility, suggesting that a postbinding swing of
CD4 cannot be the ibalizumab target. Finally, a model based
on the crystal structures of ibalizumab-2D CD4, 4 domain
CD4, and gp120 core containing the V3 loop indicates that
the coreceptor binding site on gp120 is far away from ibalizu-
mab and the antibody should not directly block gp120 binding
to the coreceptor on the cell surface.
Implications for HIV-1 Entry
Why, then, is ibalizumab a potent inhibitor of HIV-1 infection?Our
current picture of HIV-1 entry has emerged from extensive
biochemical and structural studies (Harrison, 2008). It is gener-
ally believed that sequential binding of gp120 to viral receptor
and coreceptor induces large conformational changes, which
then trigger dissociation of gp120 and a cascade of refolding
events in gp41. Structural transition of gp41 from its prefusion
conformation to the ‘‘prehairpin intermediate,’’ followed by
a six-helix bundle, postfusion conformation is the driving force
to bring viral and target cell membranes together (Chan et al.,
1997; Chan and Kim, 1998; Weissenhorn et al., 1997). Our data
strongly suggest that ibalizumab does not act on the steps prior
to coreceptor binding by gp120 but rather that it acts on a step
before gp120 dissociation or on gp120 dissociation itself.
Once gp120 falls off along with CD4 and ibalizumab, the latter
could have no influence on membrane fusion. If departure of
gp120 is the final trigger for gp41 refolding, ibalizumab could
inhibit viral infection by preventing gp120 dissociation. Interest-
ingly, mAb 5A8 does inhibit soluble CD4-induced gp120 dissoci-
ation from HIV-1 virions (Moore et al., 1992). It is also possible
that gp120 may remain bound even to triggered gp41, as in
the cases of HA1 of influenza hemagglutinin (HA) and GP1 of
Ebola glycoprotein (GP), both of which are covalently associated
with their transmembrane fusion subunit, probably throughout
the membrane fusion process (Lee et al., 2008; Wilson et al.,
1981). In this scenario, gp120 would have to coordinate with
gp41 to allow a smooth transition from the prefusion state to
the postfusion conformation via the prehairpin intermediate, in
a very crowded space. It is conceivable that ibalizumab might
obstruct certain movements of gp120 during the molecular
gymnastics required for HIV-1 entry. Many puzzles about HIV-1
membrane fusion thus remain unsolved, and ibalizumab could
present an opportunity for answering some of these questions.All rights reserved
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Expression Constructs, Cell Lines, and Protein Production
Expression constructs for his-tagged gp120 core derived from HIV-1
92UG037.8, soluble 2D (residues 1–182) and 4D (residues 1–363) human
CD4 in pFastBac-1 vector (Invitrogen) were generated by standard PCR tech-
niques. To introduce flexibility in the ectodomain of CD4, four variants with its
D3-D4 (residues 179–365) substituted by a flexible linker, GGGGS for pCD4-
L1, GGGGSGGGGSGGGGS for pCD4-L2, GGGGSGGGGSGGGGSGGGGS
GGGGSGGGGS for pCD4-L3 and GGGGSGGGGSGGGGSGGGGSGGGGS
GGGGSGGGGSGGGGSGGGGS for pCD4-L4, were created. Two additional
CD4 variants were also constructed with either a 5 residue (residues
367–371; TPVQP)deletion for pCD4-D5or theentireD3-D4, TMandcytoplamic
tail (residues 179–433) replaced by a human CD8a hinge region and TM (resi-
dues 115–214 from CD8a) for pCD4-CD8TM. Synthetic genes were made for
L1 (linker 1)-TM- CT (cytoplamic tail), L2-TM-CT, L3-TM-CT, L4-TM-CT,
CD8-hinge-TM (GENEART AG, Regensburg, Germany). These segments
were fused with D1-D2 of CD4 amplified by PCR and cloned into pcDNA 3.1
(+) (Invitrogen). pCD4-D5 was produced by produced by overlapping PCR
with primers harboring the 5 residue deletion. TZM.bl cell used for HIV-1
neutralization assays was described previously (Li et al., 2005). ACTOne Che-
mokine (C-C motif) Receptor 5 cell (Codex Biosolutions, Montgomery Village,
MD) is a stable cell line derived from 293T cells expressing human CCR5. Iba-
lizumab was provided by TaiMed Biologics (Irvine, CA) to D.D.H. F(ab’)2 frag-
ment of ibalizumabwas prepared using Pierce F(ab’)2, Preparation Kit (Thermo
Scientific) according to manufacturer’s instruction. In brief, 4 mg of ibalizumab
IgG was cleaved with 125 ml immobilized pepsin (0.2–0.3 mg; R600 units) at
37C for 6 hr, and then purified by protein A affinity chromatography. Anti-
CD4 antibody conjugated with Alexa Fluor 488 was purchased from EXBIO
Praha, Vestec,CzechRepublic; PEmouseanti-humanCD195 (CCR5) antibody
from BD Biosciences (San Jose, CA); and gp120 derived from the isolate
Du156.12 from ImmuneTechnologyCorp. (NewYork,NY).Gp120core, soluble
2Dand4DhumanCD4were expressed in insect cells andpurified by aprotocol
described previously (Rits-Volloch et al., 2006).
Crystallization and Structure Determination
Fab fragment of ibalizumab was produced by papain (Sigma) digestion at 37C
for 3 hr with an enzyme to antibody ratio of 1:10,000 byweight, and then purified
by protein A affinity and gel-filtration chromatography. 2DCD4with a C-terminal
His-tag wasmixedwith ibalizumab Fab at a molar ratio of 1:1.2 at room temper-
ature for 1 hr and the complex was further purified by gel-filtration chromatog-
raphy using a Superdex 200 column. The complex was crystallized by hanging-
drop vapor diffusion with a mother liquor containing 3 M sodium malonate
(pH 5.5). The crystals were flash-frozen in liquid nitrogen using the mother liquor
as a cryoprotectant solution. X-ray diffraction data were collected at 100 K at
beamline 24-ID, Advanced Photon Source (Argonne National Laboratory, IL).
HKL2000 (HKL Research, Inc.) was used to integrate and scale diffraction
data. The crystals diffract to 2.2 A˚ resolution and belong to space group
P212121 (a = 52.2, b = 66.3, c = 266.6 A˚), with one Fab-CD4 complex per crys-
tallographic asymmetric unit. Initial phase information was obtained by molec-
ular replacement using MOLREP and Phaser with 2D CD4 and a library of 244
different Fab coordinates as search models (Aoki et al., 2009; McCoy et al.,
2007; Vagin and Teplyakov, 1997). Complementarity determining regions
(CDRs) of both heavy and light chains of ibalizumab were rebuilt iteratively in
O (Jones and Kjeldgaard, 1997) and the final model was refined by Refmac
(Winn et al., 2001) with an Rwork of 19.3% and an Rfree of 22.4%.
Surface Plasmon Resonance Binding Assays
All experiments were performed with a Biacore 3000 instrument (Biacore Inc)
and analyzed following a protocol as described (Frey et al., 2008).
Inhibition Assays
Inhibitory activity of ibalizumab wasmeasured using amodified protocol of the
luciferase-based HIV-1 neutralization assay in TZM.bl cells as described
(Li et al., 2005; Montefiori et al., 2004). In brief, 5-fold serial dilutions of ibalizu-
mab IgG or Fab were performed in duplicate (96-well flat bottom plate) in 10%
DMEM growth medium (100 ml/well). TZM.bl cells were added (13 104/well in
50 ml volume) and the plates were incubated for 1 hr at 37C. HIV-1 Env pseu-Structure 18, 1632–16dovirus was then added (100 ml/well) in 10%DMEMgrowthmedium containing
DEAE-Dextran (Sigma, St. Louis, MO) at a final concentration of 11 mg/ml.
Assay controls included replicate wells of TZM.bl cells alone (cell control)
and TZM.bl cells with virus (virus control). Following a 48 hr incubation at
37C, 150 ml of assay medium was removed from each well and 100 ml of
Bright-Glo luciferase reagent (Promega, Madison, WI) were added and lumi-
nescence measured using a Victor 3 luminometer (Perkin Elmer). The 50%
inhibitory concentration (IC50) was calculated based on the antibody dilution
that caused a 50% reduction in relative luminescence units (RLU) compared
to the virus control wells after subtraction of cell control RLUs. For experiments
utilizing ACTOneCCR5 cells transfected with different CD4 variants as targets,
cells were added at 2x104/well. Assay stocks of molecularly cloned Env-pseu-
dotyped viruses were prepared by co-transfecting 293T/17 cells with an Env-
expressing plasmid and an Env-deficient backbone plasmid (SG3DEnv), as
described (Li et al., 2005), Specifically, recombinant HIV-1 SC422661.8 Env
pseudovirus expressing the firefly luciferase reporter gene was generated by
cotransfecting 293T/17 cells with an Env-expressing plasmid, and the
pNL4-3.Luc DEnv backbone plasmid (Raymond et al., 2008).
Small Angle X-Ray Scattering
To ensure conformational homogeneity of protein samples, 2D CD4, 4D CD4,
92UG037.8 gp120 core, 2D CD4-gp120 core complex and 4D CD4-gp120
core complex were further purified by gel-filtration chromatography using
a Superdex 200 column in a buffer containing 25 mM Tris pH 7.5, 150 mM
NaCl. Small- and wide-angle X-ray scattering (SAXS/WAXS) data were
collected using a monochromatic X-ray beam (14.18 keV) by a SAXS detector
(Mar-165 CCD) or aWAXS detector (Photonic Science) at a distance of 3.3 and
0.47 m, respectively, at beamline X9, National Synchrotron Light Source
(NSLS), Brookhaven National Laboratory. Sample-to-detector distances
were calibrated by the diffraction pattern of a standard silver behenate sample
using the program Fit2D (Hammersley et al., 1996). Scattering data were circu-
larly averaged as a function of momentum transfer vector, q (q = 4psin/q l; l is
the wavelength, and 2q is the scattering angle) by Fit2D. For each protein
sample, scattering data were collected at three different concentrations
(1, 3, and 6 mg/ml) in a flow cell. Data reduction includes normalization of
the one-dimensional scattered curve to the intensity of the transmitted beam
and subtraction of the background scattering of the buffer (25 mM Tris
[pH 7.5], 150 mM NaCl). A complete scattering plot was obtained by merging
SAXS and WAXS data at the overlapping region of q from 0.1 to 0.2 A˚-1.
Guinier analysis involves linear fitting the Guinier plot of ln[I(q)] versus q2
within a range where q$Rg <1.3 to give an estimation of the radius of gyration
(Rg) and the forward scattering intensity I(0) of the scattering sample (Guinier
and Fournet, 1955). The pair-distance distribution function P(r), which is
a measure of the frequency of interatomic vector lengths within a molecule,
yields information on the shape of the scattering particle. Guinier analysis
and P(r) analysis were performed using programs Primus and GNOM, respec-
tively (Konarev et al., 2003; Svergun, 1991). The maximum dimension (Dmax)
values, which reflect the largest dimension of the protein or protein complex,
were first calculated from the entire scattering curve I(q), in the q range from
zero to qmax, by a direct Fourier transform as described (Hong and Hao,
2009), and also analyzed by an indirect Fourier transform using GNOM.
Flow Cytometry
Transfected or untransfected 293T or ACTOne CCR5 cells were detached from
plates using 0.05% trypsin and 1mMEDTA inPBS, followedby immediate addi-
tion of complete medium containing 10% FBS, and then washed with ice-cold
PBS containing 1% BSA. 106 cells/ml were stained for 30 min at room temper-
ature with either anti-CD4 antibody conjugated with Alexa Fluor 488 (EXBIO
Praha, Vestec, Czech Republic) or PE mouse anti-human CD195 (CCR5) anti-
body (BD Biosciences, San Jose, California) diluted to 200 mg/ml in PBS con-
taining 1% BSA. Labeled cells were then washed with cold PBS with 1% BSA
and either fixed in 2.5% formaldehyde or analyzed immediately using a MoFlo
Legacy Cell Sorter and Summit Software v4.3 (Beckman Counter, Brea, CA).
ACCESSION NUMBERS
Coordinates and structure factors have been deposited in Protein Data Bank
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